Most Recent Headlines

• ANH: May 18th, 2022, 11:20Length: 9573
  Norepinephrine Drug Market Size & Top Key Players;Pfizer Inc. (NYSE: PFE), Sanofi (EPA: SAN), Mylan N.V. (NASDAQ: MYL), Cardinal Health (NYSE: CAH)
• BIZ: May 17th, 2022, 11:40Length: 27559
  Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
• SRD: May 13th, 2022, 11:19Length: 4860
  Pfizer PFE Trading Report
• PMZ: May 10th, 2022, 16:58Length: 3279
  BIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BHVN and Encourages Investors to Contact the Firm
• PSM: May 10th, 2022, 10:52Length: 1710
  Pfizer Inc (PFE) Approaches New Upside Target of $49.93
• BAY: May 10th, 2022, 09:58Length: 1789
  Pfizer Buys Biohaven for $11.6B
• BIZ: May 10th, 2022, 06:45Length: 22907
  Pfizer to Acquire Biohaven Pharmaceuticals
• PMZ: May 6th, 2022, 06:45Length: 19471
  Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE(R) for the Management of Moderate to Severe Pain Associated With Endometriosis